Schwarz R E, Iwatsuki S, Herberman R B, Whiteside T L
Pittsburgh Cancer Institute, Pennsylvania.
Hepatology. 1989 Aug;10(2):221-7. doi: 10.1002/hep.1840100217.
Lymphokine-activated killer cells were generated from peripheral blood mononuclear cells of 33 patients with liver tumors (benign, 6; primary malignant, 10; metastatic, 17) and 10 healthy individuals. Although peripheral blood mononuclear cell yield was significantly lower (p less than 0.01) in patients with hepatocellular carcinoma or with metastatic colorectal cancer, natural killer activity in the peripheral blood mononuclear cell fraction was comparable in all groups tested. Optimal lymphokine-activated killer activity was demonstrated after 9 to 12 days of culture in recombinant interleukin 2. Lymphokine-activated killer activity, interleukin 2-induced lymphocyte proliferation and total lytic activity generated per culture in all patient groups studied were similar to those of normal control cells cultured under the same conditions. These in vitro data demonstrate the feasibility of obtaining lymphokine-activated killer cells from the blood of patients with liver tumors and provide a rationale for the future use of lymphokine-activated killer cells in adoptive immunotherapy of patients with primary and metastatic hepatic neoplasms.
从33例肝肿瘤患者（良性6例、原发性恶性10例、转移性17例）及10名健康个体的外周血单个核细胞中制备淋巴因子激活的杀伤细胞。尽管肝细胞癌患者或转移性结直肠癌患者的外周血单个核细胞产量显著降低（p<0.01），但在所有测试组中，外周血单个核细胞部分的自然杀伤活性相当。在重组白细胞介素2中培养9至12天后，显示出最佳的淋巴因子激活的杀伤活性。在所有研究的患者组中，每培养物产生的淋巴因子激活的杀伤活性、白细胞介素2诱导的淋巴细胞增殖和总溶解活性与在相同条件下培养的正常对照细胞相似。这些体外数据证明了从肝肿瘤患者血液中获得淋巴因子激活的杀伤细胞的可行性，并为未来在原发性和转移性肝肿瘤患者的过继免疫治疗中使用淋巴因子激活的杀伤细胞提供了理论依据。
